Trabectedin

Fatigue, neutropenia and transaminitis: case report

A 73-year-old man developed fatigue, neutropenia and transaminitis during treatment with trabectedin for leiomyosarcoma. The man, who had leiomyosarcoma, received four cycles of doxorubicin (adriamycin) and ifosfamide in June 2011. However, after a seven month of progression-free period, an abdominal lymph node disease progression was noted. Therefore, in February 2012, he was started on trabectedin continuous infusion 1.5 mg/m² every 3 weeks. A complete remission was achieved following 26 months of the treatment. Thereafter, he continued to receive maintenance therapy with trabectedin at the same dosage. He received a total of 94 cycles of trabectedin. Meanwhile, he developed trabectedin associated grade I fatigue, grade II neutropenia and reversible grade II transaminitis [times to reactions onsets not stated; not all outcomes stated]. Eventually, he died of community-acquired pneumonia in March 2019.

Cordeiro M, et al. Long-Term Response after 94 Cycles of Trabectedin in a Patient with Metastatic Leiomyosarcoma of the Lower Extremity. Case Reports in Oncology 13:113-119, No. 1, Jan 2020. Available from: URL: http://doi.org/10.1159/000505393